<DOC>
	<DOCNO>NCT00675090</DOCNO>
	<brief_summary>This safety tolerability study investigate effect GSK239512 mild moderate Alzheimers disease patient . The dose GSK239512 titrate reach well tolerate dose patient .</brief_summary>
	<brief_title>Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Histamine H3 Antagonists</mesh_term>
	<criteria>Male female subject clinical diagnosis probable Alzheimer 's disease The subject MMSE score screen 12 26 Part A 1626 Part B . Age ≥ 50 . If female , subject must postmenopausal ( i.e . 12 month without menstrual period ) surgically sterile . Male subject must willing abstain sexual intercourse pregnant lactating woman ; willing use condom/spermicide addition female partner use another form contraception woman could become pregnant , time first dose GSK239512 84 day follow completion study . The subject ability comply study procedure . The subject permanent caregiver willing attend study visit Parts A B . The subject provide full write informed consent prior performance protocol specific procedure , unable provide inform consent due cognitive status , full write informed consent behalf subject provide legally acceptable representative . The caregiver provide / write consent prior performance protocol specific procedure . In opinion investigator , follow review CT/MRI scan past 12 month completion neurological review could probable cause dementia History significant psychiatric illness schizophrenia bipolar affective disorder opinion Investigator would interfere participation study , current depression ( score ≥8 Cornell Scale Depression Dementia ) , subject psychiatric feature AD would opinion investigator , would increase risk safety . History significant sleep disturbance , example , associate nocturnal wandering , nocturnal confusion / disorientation / agitation , opinion investigator , may increase safety risk . History presence know suspected seizure , unexplained significant loss consciousness within last 6 month . Subjects febrile seizure childhood may include ceased age 10 type seizure medical history antiepileptic medication . History presence significant cardiovascular , gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug , clinically relevant abnormality , medical psychiatric condition , , opinion Investigator , make subject unsuitable inclusion study . History alcohol substance abuse , accord Diagnostic Statistical Manual Mental Disorders Substance related disorder ( DSMIV ) criterion . Clinically significant abnormality laboratory test , include subject active liver disease uncontrolled thyroid disease . Uncontrolled hypertension systolic BP ≥160 and/or diastolic ≥95 mmHg . Subjects control hypertension systolic BP &lt; 160 mmHg diastolic &lt; 95 mmHg least 4 week acceptable . Systolic BP &lt; 100 mmHg and/or diastolic &lt; 60 mmHg . Subjects ECG criterion outside range specify protocol History hypersensitivity GSK239512 excipients . Treatment cholinesterase inhibitor , ( include Tacrine ) , memantine selegiline within previous month . No patient AD already medication time screen recruit , would unethical withdraw medication study participation . Only AD subject yet medication , withdrawn medication reason previously , may enrol study . Subjects currently take take last month antipsychotic drug ( typical atypical dopaminergic antagonist modulators ) mood stabilization drug ( include SSRI , DNRI , SNRI , MAO inhibitor , tricyclic antidepressant , lithium , valproate , carbamazepine ) . Subjects currently take Pgp inhibitor CYP3A4 inhibitor . Subjects chronic sedative medication ( ≥ 4 day per week past 4 week ) . Subject caregiver immediate family member employee participate Investigator , participate site staff GSK staff . Has receive investigational treatment previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimers Disease</keyword>
</DOC>